Peptide RX

back to claim graph

proof receipt / target

CHRNA7

Alpha-7 nicotinic acetylcholine receptor

grade B status cognitive receipt ea79efffc23d proof 33%

what this node claims

CHRNA7

Alpha-7 nicotinic acetylcholine receptor

Open source surface

vertical proof spine

  1. 01 CHRNA7 target / grade B / 70% 1 debt
  2. 02 CHRNA7 WT fold / grade B / 62% 2 debt

evidence / risk instrument

44%
thin proof
structure evidence gates risk export lineage 44
low debt pressure 21%
28%structuredebt
pLDDT pending
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine

proof completeness

33% missing alphafold_metric, candidate, finding, export
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

binding partners
    context annotations
    0
    family
    ligand_gated_ion_channel
    functional sites
      gene symbol
      CHRNA7
      go terms
        uniprot
        P36544

        AlphaFold metrics visual

        Confident backbone model

        78.3

        502 residues / min 28.12 / max 96.94 / source alphafold db

        PAE matrix for linked target
        Very high 38.4% 193 residues / >=90
        Confident 38.2% 192 residues / 70-89
        Low 7.4% 37 residues / 50-69
        Very low 15.9% 80 residues / <50

        usable fold context with explicit model-confidence limits

        Near-complete coverage / observed 502 of 502 residues.

        • residues 346-430 / mean 37.37
        • residues 1-21 / mean 57.58
        • residues 322-325 / mean 68.91
        • residues 500-502 / mean 62.88
        proof debt register

        Visible limits, not hidden cleanup.

        21%

        Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

        medium missing functional-site annotations link target annotation, GO term, or binding-site context
        low computational-only status add independent evidence, challenge result, or witness review before strengthening
        medium no candidate yet leave visible until a stronger public receipt resolves it

        weakness and challenge edges

        What would stop this from becoming stronger.

        debt severity export claim strength next proof needed
        missing functional-site annotations medium visible weakens link target annotation, GO term, or binding-site context
        computational-only status low visible watch add independent evidence, challenge result, or witness review before strengthening
        no candidate yet medium visible weakens leave visible until a stronger public receipt resolves it

        what supports it

        No upstream proof edge yet.

        what it supports

        target has structure prediction target:fc5e5ff4-7348-4d45-85b4-c33c3a8457eb -> fold:fcd130e6-5f75-472b-a4ca-c6e8fc43176e folds_to / B / 0.783

        Research-use boundary

        This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.